Abstracts tagged "Disease Activity"

Abstract Number: 709 • 2014 ACR/ARHP Annual Meeting
Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).
Lilian Reis¹, Marco Tulio de Mello² and Virginia M. Trevisani³, ¹Internal medicine and therapy, Federal University of Sao Paulo - UNIFESP, SAO PAULO, Brazil, ²Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ³Federal University of São Paulo, São Paulo Brazil, Brazil
Background/Purpose Despite the fact that sleep disorders are poorly studied, they´re a frequent complain by patients with SLE (62 to 80% related) and others found…
Abstract Number: 383 • 2014 ACR/ARHP Annual Meeting
How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry
Edward C. Keystone¹, Boulos Haraoui², John Kelsall³, Carter Thorne⁴, Philip Baer⁵, William Bensen⁶, Denis Choquette⁷, Regan Arendse⁸, Dalton Sholter⁹, Niall Jones¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, May Shawi¹³, Allen J Lehman¹⁴ and Susan Otawa¹⁴, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Montreal Hospital Centre, Montreal, QC, Canada, ³The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹194 Main Street, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Composite measures of disease activity can facilitate clinical decision-making to achieve treatment goals, and treating-to-target has been shown to improve outcomes. Both CRA and…
Abstract Number: 136 • 2014 ACR/ARHP Annual Meeting
Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis
Jana Hurnakova¹, Jakub Zavada¹, Petra Hanova², Hana Hulejova¹, Martin Klein¹, Herman F. Mann¹, Olga Sleglova¹, Martina Olejarova¹, Sarka Forejtova³, Olga Ruzickova¹, Martin Komarc⁴, Karel Pavelka¹ and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Institute of biophysics and informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose Serological biomarkers specifically reflecting pathological processes may have added value in assessing joint inflammation in rheumatoid arthritis (RA). Calprotectin (S100A8/9 protein) has been demonstrated…
Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting
Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients. This analysis…
Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting
Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis
Aziza Elmesmari¹, Derek G. Gilchrist², Mariola Kurowska-Stolarska³ and Iain B. McInnes⁴, ¹Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span. MicroRNA 155 (miR155) is particularly implicated in…
Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder¹, Eric Zollars², Jadwiga Bienkowska³, Chris Stebbins⁴, Carrie Wager⁵, Linda Burkly⁶, Nicolas Wisniacki⁷, Ann Ranger⁸ and Michelle Petri⁹, ¹Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Translational Medicine, Biogen Idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec, Cambridge, MA, ⁷Formerly with Biogen Idec, Cambridge, MA, ⁸14 Cambridge Center, Biogen Idec, Cambridge, MA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…
Abstract Number: 1426 • 2014 ACR/ARHP Annual Meeting
Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients
Daniel Xibille-Friedmann¹, Jose Ivan Martinez Rivera², Jaqueline Rodriguez Amado³, Carolina Bustos Rivera Bahena⁴, Marisol Sandoval Rios⁵ and Jose Luis Montiel Hernandez⁶, ¹Rheumatology, Hospital General de Cuernavaca, Cuernavaca, Mexico, ²Instituto Nacional de Salud Publica, Cuernavaca, Mexico, ³Universidad Autónoma de Nuevo Leon, Centro de Investigación y Desarrollo en Ciencias de la Salud, Monterrey, Mexico, ⁴Universidad Autonoma del Estado de Morelos, Science Faculty, Cuernavaca, Mexico, ⁵Universidad Autonoma del Estado de Morelos, Faculty of Pharmacy, Cuernavaca, Mexico, ⁶Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México, Cuernavaca, Mexico
Background/Purpose: Although several studies have suggested the association between periodontitis, infection by Porphyromona gingivalisand Rheumatoid Arthritis disease activity, its relationship with periodontal disease, oral and…
Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain², Amy Mudano³ and George Wells⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…
Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting
Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Sarah Al Sawah¹, Xiang Zhang¹, Baojin Zhu¹, Laurence S. Magder², Shonda A Foster¹, Noriko Iikuni¹ and Michelle Petri³, ¹Eli Lilly and Company, Indianapolis, IN, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…
Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Arthritis Research Centre of Canada, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…
Abstract Number: 128 • 2014 ACR/ARHP Annual Meeting
A Rapid 4- Joint Ultrasonographic Score to Daily Monitoring Disease Activity in Patients with Rheumatoid Arthritis: Validity and Sensitivity to Change
Tomas Cazenave¹, Christian A. Waimann², Gustavo Citera³ and Marcos G. Rosemffet⁴, ¹Junin 519 1ero B, IREP, Buenos Aires, Argentina, ²Rheumatology, Hospital Olavarria, Olavarria, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose Ultrasound has demonstrated to be a sensitivity and specific tool to assess patients with Rheumatoid Arthritis (RA). However, the feasibility of this technology in…
Abstract Number: 2636 • 2014 ACR/ARHP Annual Meeting
Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
John A. Reynolds¹, David W. Ray², Terence O'Neill³, Yvonne Alexander⁴ and Ian N. Bruce^5,6, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose SLE patients have an increased risk of cardiovascular disease (CVD). Vitamin D deficiency has been associated with both CVD risk factors and subclinical CVD…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Paul Studenic¹, Josef Smolen² and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine 3, Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].